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TObjective: Implantation of bioprostheses in the supra-annular position with the
single suture line was first applied by O’Brien to porcine stentless valves. The aim
of this study was to evaluate the clinical performance of the Pericarbon Freedom
stentless bioprosthesis (Sorin Biomedica Cardio, Saluggia, Italy) implanted in
supra-annular position with the single–suture line technique. The single-suture
approach for the Pericarbon Freedom stentless bioprosthesis is obtained by trim-
ming away all the extra tissue of the valve inflow side and scalloping the outflow
side.
Methods: Between February 2002 and August 2004, a total of 65 consecutive
patients at our institution (48% male, mean age 69  12 years) underwent aortic
valve replacement with Pericarbon Freedom stentless bioprostheses implanted with
a single suture line. Most recurrent etiology was senile degeneration (80%). Peri-
carbon Freedom 25-mm and 27-mm valves were the most frequently implanted.
Thirty patients had concomitant procedures (mainly coronary artery bypass grafting,
16 patients). Overall crossclamp time was 76  21 minutes.
Results: All patients survived intervention. One patient died early of multiorgan
failure (postoperative day 16). There were 4 early non–valve-related complications
and no late complications at a mean follow-up of 491  270 days. Four patients
showed trivial central prosthetic regurgitation at intraoperative transesophageal
echocardiography; among these cases, only 1 was confirmed at 6-month transtho-
racic echocardiography. At postoperative echocardiographic assessment, mean pres-
sure gradient for the 25- through 29-mm size group was 10.2  7.1 mm Hg, and
peak pressure gradient was 18.1  12.3 mm Hg.
Conclusion: Our initial experience combined a well-established supra-annular im-
plantation technique with the Pericarbon Freedom stentless bioprosthesis, a latest-
generation pericardial stentless valve. The combination showed excellent results in
terms of safety and reliability, although this technique required adequate experience.
Clinical outcomes are similar to those obtained with other techniques, with satis-
factory hemodynamic performance.
Since the introduction of stentless bioprostheses for aortic valve replacement,1a variety of models have been made available.2-4 According to O’Brien,5 theideal stentless prosthesis should have no synthetic materials, preserve the
aortic root dynamics, restore flexibility and distensibility of the native valve annulus
after decalcification, and have minimal xenograft aortic wall, short implantation
time, and excellent hemodynamic performance to facilitate the recovery of left
ventricular function.
With this in mind, we investigated the use of the Pericarbon Freedom (PF)
stentless bioprosthesis (Sorin Biomedica Cardio, Saluggia, Vercelli, Italy) with a
simplified supra-annular implantation technique. The prosthesis, available since
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CD1991, consists of cross-linked bovine pericardium and has
been redesigned in 2000 with the addition of a posttreatment
step aimed at removing aldehyde residues.6 The valve de-
sign includes pericardium only, which forms the leaflets and
extends toward inflow and outflow to allow surgical suture
placement.
The PF bioprosthesis is provided by the manufacturer
with extra tissue, allowing intraoperative tailoring for adap-
tation to local anatomy and the surgeon’s technique. The
valve has been implanted with two suture lines (interrupted or
continuous stitches on the inflow side and continuous stitches
on the outflow side).7,8 The alternative single–suture line tech-
nique allows correct supra-annular positioning of the prosthe-
sis, avoiding any nonvalvular tissue in the outflow tract.
Methods
Operative Technique
The patient is placed on normothermic cardiopulmonary bypass
with a central temperature of 37°C. Myocardial preservation is
achieved by antegrade cold (St. Thomas’ Hospital) crystalloid
cardioplegia through the coronary ostia at 700 to 1000 mL. Addi-
tional 300-mL doses are repeated every 30 minutes. Transverse
aortic incision is made about 1 cm above the sinotubular junction,
wide enough to completely visualize the valve. Separation of the
Abbreviations and Acronyms
PF  Pericarbon FreedomFigure 1. Outflow scalloping
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excision of the valve and decalcification of the annulus, the aortic
orifice is measured with a Hegar probe. The prosthetic valve is
chosen according to the rule of one size more or 2 mm larger than
the orifice. The single-suture approach is made possible by trim-
ming away all the extra tissue of the valve inflow side and
scalloping the outflow side (Figure 1). The valve assembly suture
is preserved and is anchored with an extra stitch on the external
side of the corresponding commissure, to be placed at the left
noncoronary commissure of the native annulus. No rinsing in
saline solution is necessary, because the valve is already prepared
for implantation.
The implantation surgical technique is derived from O’Brien 9,10
as follows: three equidistant 4-0 polypropylene sutures on a small
taper-cut semicircular needle are placed in supra-annular position
near the midpoint, at 2 to 3 mm from the host annulus of each
sinus, exiting further out in the supra-annular sinus wall (Figure 2).
Placement of the sutures below or through the annulus should be
avoided. Once the valve is seated just above the host annulus in a
supra-annular position, each of the three sutures must be tied,
leaving equal lengths, six in all, that are used to suture the valve to
the host along and up to the top of the commissures, starting with
the right coronary sinus (A), the left coronary sinus (B), and then
the noncoronary sinus (C, Figure 3).
A moderate traction on the valve during suturing makes easier
the supra-annular running suture. The valve is secured in place
with deep, almost full-thickness bites to the host aortic wall (Fig-
ure 4). Care should be taken to avoid needle damage to the leaflet
tissue.
Both sutures from each side are prolonged to the top of the
commissure, with an ending knot being placed outside the aorta onand inflow trimming.
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CDa polytetrafluoroethylene felt. Aortotomy is closed in a standard
way with a 5-0 polypropylene running suture.
Indications and Contraindications
The indications for the PF stentless for supra-annular implantation
are as follows: (1) Elderly patients with symmetric aortic root and
trileaflet valve-sinus anatomy are the ideal patients. (2) Patients
older than 60 years are candidates for this valve. Younger patients
wishing to avoid anticoagulation and a mechanical valve and those
for whom a homograft is not available may be candidates. (3) Patients
Figure 2. Continuous suture line for subcoronary attachment: first
step.Figure 3. Continuous suture line order for subcoronary attachment.
The Journal of Thoracicwith active endocarditis without periannular abscesses are candi-
dates. The single rare contraindication to the use of this technique
is massive calcification of the aortic sinus wall and root, which
makes the supra-annular suturing impossible.
In addition to the preceding, two particular features should also
be taken into account. Bicuspid valve is not a real contraindication,
although directly opposing coronary ostia (ie, 180°) may present a
difficult orientation of the valve toward the coronary ostia. In case
of concomitant aortic ectasia with dilatation of the sinotubular
junction (2 mm larger than the annulus), ascending aorta replace-
ment is mandatory to avoid valve incompetence.
Study Population
Between February 2002 and August 2004, a total of 65 consecutive
patients received the PF stentless valve with a single–suture line
implant technique for aortic valve replacement. All implantations
were performed by a single surgeon (A.R.). The study comprised
31 male and 34 female patients ranging in age from 26 to 87 years
(mean 69  12 years). Informed consent was requested from the
patients in all cases, according to the rules and regulations of the
internal review board of our institution.
Preoperative and intraoperative transesophageal echocardio-
graphic and postoperative echocardiographic analyses were carried
out at 1 week after implantation and again at 6 months. In addition
to the usual gradient measurements, effective orifice area was also
calculated. Clinical status and both type and frequency of postop-
erative complications were evaluated on the basis of the revised
guidelines.11 Mean follow-up was 491  270 days (range 987-29
days). Completeness of the follow-up was 100%. Color Doppler
echocardiography was performed with a Philips Sonos 5500 sys-
tem (Philips Medical System, Eindhoven, The Netherlands)
equipped with a 2.5- to 3.5-MHz transducer. Standard M-mode
and 2-dimensional measurements were collected according to the
Figure 4. Continuous suture line for subcoronary attachment.criteria of the American Society of Echocardiography.12 All Dopp-
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patients with sinus rhythm or more than five cycles in those with
atrial fibrillation.
The reasons for valve replacement are shown in Table 1.
Concomitant surgery was performed in 30 cases (46%). The most
common procedure was coronary artery bypass grafting in 16
patients (Table 2).
Valve size distribution was as follows: 2 size 21 mm (3%), 3
size 23 mm (5%), 25 size 25 mm (38%), 29 size 27 mm (45%), and
6 size 29 mm (9%). A bicuspid valve was found in 6 cases; this
was not considered a contraindication for a stentless valve.
Results
There was 1 early death (1.5%), of multiorgan failure on
postoperative day 16. The patient, aged 80 years and with
low ventricular function (ejection fraction 35%) underwent
aortic valve replacement, mitral annuloplasty, myocardial
revascularization, and radiofrequency ablation for atrial fi-
brillation. Death occurred after a complicated postoperative
course with low cardiac output and fatal multiorgan failure.
Postoperative echocardiography showed normal aortic valve
function.
Mean implantation time was 30  8 minutes. Mean
crossclamp times were 62 18 minutes for patients without
concomitant procedures and 76  21 minutes overall.
Early morbidity included 4 patients (6.1%) with non–valve-
related complications: 1 pacemaker implantation in a patient
with associated tricuspid repair, 2 renal or respiratory tran-
sient failures, and 1 transient low cardiac output syndrome
necessitating intravenous inotropic support. One female pa-
tient, aged 67 years and with associated myocardial revas-
cularization, had endocarditis with extensive periannular
abscess 2 months after the operation. Nevertheless, no aortic
regurgitation was present, and at reoperation the prosthesis
was found to be firmly anchored to the aortic wall. The
postoperative course was uneventful, as was the follow-up. No
other late complications were reported at follow-up. No late
deaths occurred.
Echocardiographic Analysis
Four patients had trivial central prosthetic regurgitation at
intraoperative transesophageal echocardiography. Only 1 case
was confirmed at 6-month echocardiographic examination.
Peak pressure transvalvular gradient related to the 25-
TABLE 1. Etiology of valve disease
No. %
Senile degeneration or calcification 52 80
Congenital monocuspid or bicuspid valve 6 9
Endocarditis 3 5
Rheumatic 3 5
Degenerative myxomatosis 1 1through 29-mm size group (92.3% of the patient cohort) at
1268 The Journal of Thoracic and Cardiovascular Surgery ● Nov1 postoperative week was 18.1  12.3 mm Hg. Mean aortic
transvalvular gradients were 10.2  7.1 mm Hg at 1 post-
operative week and 8.0 4.3 mm Hg at 6 months. Effective
orifice area at 6 months was 2.14  0.50 cm2. Mean
pressure gradients and effective orifice areas for the 21-
through 29-mm sizes are reported in Table 3.
Discussion
This is the first clinical application of a true supra-annular
technique with a single suture line, as described by
O’Brien9,10 for the CryoLife-O’Brien porcine stentless
valve (CryoLife Inc, Kennesaw, Ga), on a pericardial stent-
less valve. The early results of the preliminary series of the
PF stentless valve with single–suture line implantation tech-
nique have been satisfactory. Clinical outcomes were sim-
ilar to those obtained with other techniques7,14; hemody-
namic performance was excellent, and residual
regurgitation was negligible. Overall implantation time was
dramatically reduced.
In clinical practice, the PF stentless valve is optimal for
supra-annular implantation for virtually all patients who
otherwise would be receiving a stented bioprosthesis. In our
consecutive series, no patient was excluded for technical or
anatomic reasons.
The supra-annular positioning with PF stentless biopros-
thesis shows many advantages. The effective orifice area is
maximized, allowing 100% orifice-annulus match and the
implantation of the largest valve orifice available. The blood
flow from the ventricle to the aorta is streamlined laminar,
and the transvalvular gradients are as low as those of an
allograft aortic valve. We report a mean gradient of 10.4 
5.6 mm Hg for a 25-mm valve (annulus diameter 23 mm)
TABLE 2. Concomitant procedures
No. %
Coronary artery bypass grafting 16 24.6
Resection of aortic aneurysm 6 9.2
Tricuspid or mitral valve repair 6 9.2
Septal myectomy 1 1.5
Radiofrequency ablation 1 1.5
TABLE 3. Results of transthoracic echocardiography for
21- to 29-mm sizes at 6-month follow-up
Label size
Mean pressure
gradient (mm Hg)
Effective orifice
area (cm2)
21 mm (n  2) 13.5 2.1 1.7  0.5
23 mm (n  3) 12.7 5.8 1.9  0.6
25 mm (n  25) 10.4 5.6 2.0  0.5
27 mm (n  29) 6.5  4.3 2.2 0.5
29 mm (n  6) 5.0  3.2 2.4 0.4
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ison, in a local retrospective cohort, the 25-mm valve, with
two-suture technique, had a mean gradient of 12.1  4.2
mm Hg and an effective orifice area of 1.9  0.4 cm2.
In making a comparison between the two implantation
techniques, it should be noted that for a given annular
diameter, the supra-annular placement allows a size larger
valve. Moreover selecting a valve a size larger than the host
annulus maximizes the leaflet coaptation. The stress on the
suture line is better absorbed, avoiding the chiseling effect
that arises when the stentless valve is implanted in intra-
annular position.13
Bovine pericardium is resistant and fully retains the
sutures without any risk of tearing, as has been reported
with the aortic porcine wall.15 In addition, it is smooth and
thin and adapts well to the host tissue, minimizing the risks
of perivalvular leaks. Leaks were not observed in any cases
in our series.
Moreover, there is no valve tissue inside the annulus and
in the outflow tract except the leaflets, which are supra-
annularly anchored to the aortic wall. Trimming away all
the prosthetic pericardial tissue of the inflow tract is impor-
tant, because no tissue has to be fixed below the leaflets and
a single continuous suture line is sufficient to anchor this
valve into place.
Placement of the sutures below or through the annulus
should be avoided, because intra-annular implantation could
have a negative effect on transvalvular gradients. Deep,
almost full-thickness bites of the host aortic wall are rec-
ommended to secure the valve into place. Deep, broad bites
on the outflow pericardial strips are to be performed as well,
close to the leaflet attachment and to the black assembling
suture. In this way there should be virtually no potential
space behind the commissural posts and no ledge under-
neath the leaflet from the ventricular aspect, with no pro-
jection of tissue into the orifice during systole.
The single–suture line technique avoids any peripros-
thetic dead space between prosthetic valve and native aortic
wall. Last but not least, a single continuous suture line is
simple and quick, saving time, which is especially advan-
tageous when concomitant cardiac procedures are required.
Our experience combines a well-established truly supra-
annular implantation technique with a latest-generation
pericardial stentless valve that is now available pretrimmed
(Freedom Solo).
The Journal of ThoracicThese early favorable results need to be borne out by
longer and more comprehensive studies of larger groups.
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